Overview

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed extensive stage small cell lung cancer, who progressed on PD-(L)1 -based first-line therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

irinotecan sucrosofate